Novo Nordisk A/S (NYSE:NVO) Hits New 52-Week Low - Time to Sell?

Novo Nordisk A/S (NYSE:NVO - Get Free Report) reached a new 52-week low during trading on Wednesday . The stock traded as low as $73.20 and last traded at $73.57, with a volume of 8872312 shares. The stock had previously closed at $75.33.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Price Performance

The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $311.23 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 0.90 and a beta of 0.42. The business's fifty day moving average price is $82.33 and its 200-day moving average price is $98.89.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's payout ratio is currently 47.72%.

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently made changes to their positions in the company. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S in the 3rd quarter worth about $28,000. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL increased its position in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Transce3nd LLC purchased a new position in Novo Nordisk A/S in the fourth quarter worth $33,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.